EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein
Carolin Offenhäuser1, Keyur A Dave2, Kirrilee J Beckett3
1Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia. Carolin.Offenhauser@qimrberghofer.edu.au.
Abstract:
Prostate cancer morbidity and mortality demonstrate a need for more effective targeted therapies. One potential target is EphA2, although paradoxically, pro- and anti-oncogenic effects have been shown to be mediated by EphA2. We demonstrate that unique activating and blocking EphA2-targeting monoclonal antibodies display opposing tumor-suppressive and oncogenic properties in vivo. To further explore this complexity, we performed detailed phosphoproteomic analysis following ligand-induced EphA2 activation. Our analysis identified altered phosphorylation of 73 downstream proteins related to the PI3K/AKT/mTOR and ERK/MAPK pathways, with the majority implicated in cell junction and cytoskeletal organization, cell motility, and tumor metastasis. We demonstrate that the adapter protein SHB is an essential component in mediating the inhibition of the ERK/MAPK pathway in response to EphA2 receptor activation. Furthermore, we identify the adherence junction protein afadin as an EphA2-regulated phosphoprotein which is involved in prostate cancer migration and invasion.
Insights
Targeting EphA2 in prostate cancer shows complex effects. Specific antibodies have opposing impacts, influencing tumor growth and metastasis through key signaling pathways like PI3K/AKT/mTOR and ERK/MAPK.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Prostate cancer necessitates novel targeted therapies due to significant morbidity and mortality.
- EphA2 receptor tyrosine kinase presents a paradoxical target, exhibiting both pro- and anti-oncogenic roles.
- Understanding EphA2's complex functions is crucial for developing effective prostate cancer treatments.
Purpose of the Study:
- To investigate the dualistic functions of EphA2 in prostate cancer.
- To elucidate the downstream signaling pathways affected by EphA2 activation.
- To identify key molecular players mediating EphA2's effects on cancer cell behavior.
Main Methods:
- Utilized EphA2-targeting monoclonal antibodies with distinct in vivo properties.
- Performed comprehensive phosphoproteomic analysis after ligand-induced EphA2 activation.
- Investigated the roles of SHB and afadin in EphA2-mediated signaling.
Main Results:
- EphA2-targeting antibodies demonstrated opposing tumor-suppressive and oncogenic effects.
- Identified 73 downstream phosphoproteins altered by EphA2 activation, linked to PI3K/AKT/mTOR and ERK/MAPK pathways.
- Discovered SHB as critical for EphA2-mediated ERK/MAPK inhibition and afadin as an EphA2-regulated protein involved in prostate cancer cell migration.
Conclusions:
- EphA2's role in prostate cancer is complex and context-dependent.
- SHB and afadin are key mediators of EphA2 signaling in prostate cancer progression.
- Targeted modulation of EphA2 signaling pathways offers potential therapeutic strategies for prostate cancer.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Regulation of Angiogenesis and Blood Supply
Cell-matrix's Response to Mechanical Forces
Anchoring junctions mechanically attach a cell to the...
Intracellular Signaling Affects Focal Adhesions
Some...
Adherens Junctions
Adherens Junctions are Dynamic
Anchoring Junctions


